FDA slams Actelion amid BMS buyout rumors
In a warning letter, FDA scolds Actelion for failing to report 3,500 deaths in patients using the company's drugs Tracleer and Ventavis, both treatments for pulmonary arterial hypertension.
There's good news and bad news for the Swiss biotech Actelion today. First, the company's stock is up 6.6 percent on news that Bristol-Myers Squibb may announce that it owns more than 3 percent of the company, as Swiss law requires. That, in turn, has fueled speculation that BMS might take over the company completely.
However, the company is in hot water with the FDA for keeping some life-and-death information to itself. In a warning letter, the agency scolds Actelion for failing to report 3,500 deaths in patients using the company's drugs Tracleer and Ventavis, both treatments for pulmonary arterial hypertension.
Sign up for our FREE newsletter for more news like this sent to your inbox!
Now, the FDA does emphasize that the drugs treat a condition that in itself can cause death. And, the agency says, "we are not concluding or implying that the patients' deaths ... would ultimately be determined to have been caused by their use." Nevertheless, the agency says
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance